Venture Life Regulatory News (VLG)

21 February 2020

Venture Life Group plc

("Venture Life" the "Company" or the "Group")

Director/PDMR Shareholding

Venture Life Group plc (AIM: VLG), a leader in developing, manufacturing and commercialising products for the international self-care market, announces that, following his son's eighteenth birthday, Group CEO, Jerry Randall's beneficial interest in ordinary shares of 0.3 pence each of the capital of the Company ("Ordinary Shares") has reduced by 141,000 Ordinary Shares. Accordingly, Jerry Randall now has a beneficial interest in 3,769,729 Ordinary Shares, representing approximately 4.5 per cent. of the Group's issued share capital.

For further information, please contact:

 About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the global self-care market. With operations in both the UK and Italy, the Group's product portfolio includes some key products such as the UltraDEX and Dentyl oral care product ranges, food supplements for maintaining brain function, medical devices for women's intimate healthcare and proctology and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies and grocery multiples. In the UK these are supplied direct by the company, outside of the UK they are supplied by the Group's international distribution partners. 

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.